Revolutionizing Influenza Diagnosis: Mobilo Diagnostics Launches Truenat H3N2/H1N1 Point-of-Care Test

Highlights:

Mobilo Diagnostics has announced the release of Truenat H3N2/H1N1, the first point-of-care Real-Time PCR test that aids in the confirmed diagnosis of influenza infections
The Central Drugs Standard Control Organization (CDSCO) has approved the test, which can produce results in an hour and will run on current Truenat equipment in over 3500 PHCs/CHCs and over 1200 private labs and hospitals across India
Truenat is a portable, battery-powered, IoT-enabled, multi-disease, Real-Time PCR platform that provides testing for over 40 diseases, including COVID-19, tuberculosis, HCV, HBV, HIV, HPV, Dengue, Malaria, Influenza, Nipah, and typhoid

Mobilo Diagnostics announced the release of the Truenat H3N2/H1N1 for the differential diagnosis of the H3N2 and H1N1 viruses. The Central Drugs Standard Control Organization (CDSCO) has approved the test, which may produce results in an hour.

H3N2 Virus Spread in India: Here's How To Prevent
How to prevent H3N2 influenza virus infection? Living a healthy lifestyle and following precautionary measures are important to stop the spread of H3N2 infection.

‘Revolutionizing influenza diagnosis in India! Mobilo Diagnostics launches Truenat H3N2/H1N1, the first point-of-care Real-Time PCR test approved by CDSCO for a confirmed diagnosis of influenza infections with quick and accurate results.’

Tweet it Now

First Point-of-Care Real-Time PCR Test for Confirmed Diagnosis of Influenza Infections

Truenat H3N2/H1N1 is the first point-of-care Real-Time PCR test that aids in the confirmed diagnosis of influenza infections, according to the diagnostics business. The test will run on current Truenat equipment in over 3500 PHCs/CHCs and over 1200 private labs and hospitals across India, allowing patients to receive a rapid diagnosis at all levels of the healthcare chain.

India is now experiencing an increase in influenza virus infections caused by H3N2 and H1N1. The viruses that transmit through the air have the potential to produce an influenza pandemic due to their capacity to maintain human-to-human transmission.

H3N2, Swine Flu, and COVID-19 Make Their Round Abouts in India
H3N2, Swine Flu, and COVID-19 are spreading like wildfire throughout the country.

Truenat: A Game Changer in Influenza Diagnosis and Management

“The launch of Truenat H3N2/H1N1 further strengthens Molbio’s product portfolio by providing complete testing solutions for respiratory illnesses. The multi-disease testing capability of the Truenat platform keeps healthcare facilities prepared to combat all kinds of pandemics and disease outbreaks at an early stage. Going forward, Molbio will continue to bring innovative solutions for better patient management and appropriate treatment of the disease,” Sriram Natarajan, CEO, Founder, and Director, of Molbio Diagnostics, said in a statement.

New Vaccine Protects Against All Strains of H3N2 Influenza
A vaccine called COBRA vaccine that protects against multiple co-circulating strains of H3N2 influenza isolated over five seasons has been developed.

Advantages of Truenat H3N2/H1N1 Test

Truenat, according to the diagnostics firm, has been a game changer in this regard as a point-of-care molecular platform that provides more than 40 tests immediately at the moment of need.

Polymerase Chain Reaction (PCR) and Real-Time PCR are molecular technologies that are transforming illness diagnosis and management. In this regard, Truenat, a point-of-care, portable, battery-powered, IoT-enabled, multi-disease, Real-Time PCR platform, has been a game changer. Truenat provides testing for over 40 diseases, including COVID-19, tuberculosis, HCV, HBV, HIV, HPV, Dengue, Malaria, Influenza, Nipah, and typhoid.

Source-Medindia